clinical trial · NCT06295952
A Study of Pasireotide in People With Prolactinoma
Prolactin-Producing Pituitary TumorPasireotideSF-36 and HADS
brief summary
The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma.
started
Feb 27, 2024
primary completion
Feb 1, 2027
completion
Feb 1, 2027
last updated
Mar 4, 2026
official title
Pasireotide Treatment for Patients With Prolactinomas Who Need Treatment Beyond Dopamine Agonist Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol